Analyst Reco. iTeos Therapeutics, Inc.

Equities

ITOS

US46565G1040

Market Closed - Nasdaq Other stock markets 16:00:00 2024-04-26 EDT			5-day change	1st Jan Change
10.8 ^USD	+1.89%		+2.27%	-1.37%

03-13	Top Premarket Decliners	MT
03-12	JPMorgan Adjusts Price Target on iTeos Therapeutics to $27 From $29, Maintains Overweight Rating	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

JPMorgan Adjusts Price Target on iTeos Therapeutics to $27 From $29, Maintains Overweight Rating	03-12	MT
Wedbush Adjusts iTeos Therapeutics Price Target to $18 From $25, Maintains Outperform Rating	03-06	MT
JPMorgan Cuts Price Target on iTeos Therapeutics to $29 From $32, Maintains Overweight Rating	11-13	MT
HC Wainwright Adjusts Price Target on iTeos Therapeutics to $44 From $54, Maintains Buy Rating	23-08-09	MT
JPMorgan Chase Adjusts Price Target on iTeos Therapeutics to $32 From $34, Maintains Overweight Rating	23-03-16	MT
Wedbush Lowers iTeos Therapeutics' Price Target to $33 From $45 Following Model Update; Keeps Outperform Rating	23-03-16	MT
Wedbush Lifts Price Target on iTeos Therapeutics to $45 From $42, Keeps Outperform Rating	22-08-11	MT
Wedbush Adjusts Price Target on ITeos Therapeutics to $42 From $49, Citing EOS-448 Launch Estimates; Outperform Rating Kept	22-05-13	MT
Piper Sandler Adjusts Price Target on ITeos Therapeutics to $34 From $42, Reiterates Overweight Rating	22-05-12	MT
Wedbush Removes Outperform-Rated ITeos Therapeutics From Best Ideas List; Price Target is $49	22-05-06	MT
Wedbush Lifts ITeos Therapeutics' Price Target to $49 From $48; Outperform Rating Kept	21-12-16	MT
HC Wainwright Adjusts iTeos Therapeutics' Price Target to $54 from $37, Keeps Buy Rating	21-12-13	MT
Piper Sandler Adjusts iTeos Therapeutics' Price Target to $42 From $50, Reiterates Overweight Rating	21-11-11	MT
Wedbush Lowers ITeos Therapeutics' Price Target to $48 From $52; Outperform Rating Kept	21-11-11	MT
ITEOS THERAPEUTICS : Wedbush Lifts ITeos Therapeutics' Price Target to $52 From $50, Keeps Outperform Rating	21-08-13	MT
ITEOS THERAPEUTICS : Wedbush Adjusts ITeos Therapeutics' Price Target to $50 From $52, Keeps Outperform Rating	21-06-15	MT
ITEOS THERAPEUTICS : SVB Leerink Adjusts Price Target on ITeos Therapeutics to $45 From $60, Maintains Outperform Rating	21-05-19	MT
ITEOS THERAPEUTICS : HC Wainwright Starts ITeos Therapeutics at Buy With $37 Price Target	21-05-05	MT
ITEOS THERAPEUTICS : SVB Leerink Adjusts Price Target on iTeos Therapeutics to $60 From $37, Maintains Outperform Rating	21-04-06	MT
ITEOS THERAPEUTICS : Wedbush Raises Price Target for iTeos Therapeutics Ahead of Potentially Upbeat EOS-448 Data, Maintains Outperform Rating	21-03-25	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. iTeos Therapeutics, Inc.

Equities

ITOS

US46565G1040

Analyst Reco.

Filters